Diabetes · Question 51 of 60

Mrs R., 56, has severe overweight and coronary heart disease after a heart attack, but no diabetes. Which statement about GLP-1 receptor agonists is correct?

1 answer is correct. Hard Created with AI

Show answer

Answer

  • D In a large trial, semaglutide cut major cardiac events by about one fifth

Explanation

In the SELECT trial (NEJM 2023), semaglutide reduced major cardiovascular events by about 20 per cent in people with overweight and cardiovascular disease but without diabetes. Whether such a drug is suitable is decided by the doctor in each individual case.

Certifications & exams

Which exam comes next?

You can already practise for 51 exams, and 16 are up for a vote. See all certifications with their official information, cast your vote or suggest your exam.

See all certifications